Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGN002 Extension Study in Refractory NHL
NCT02847949Phase 1Withdrawn
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jan 2021
- Primary completion
- Jul 2025
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eramkafusp alfa in non-Hodgkin lymphoma (NHL), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start Jan 2021; status: withdrawn.
02
Drugs
eramkafusp alfa
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02847949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847949.